3 years ago

Pharmacokinetic/pharmacodynamic drug-drug interactions of avatrombopag when co-administered with dual or selective CYP2C9 and CYP3A interacting drugs

Peter Boyd, Y. Amy Siu, Jagadeesh Aluri, Bhaskar Rege, Min-Kun Chang, Edgar Schuck, Maiko Nomoto, Sanae Yasuda, W. George Lai, Jim Ferry, Cynthia A. Zamora
Aims Avatrombopag, a thrombopoietin receptor agonist, is a substrate of cytochrome P450 (CYP) 2C9 and CYP3A. We assessed three drug-drug interactions of avatrombopag as a victim with dual or selective CYP2C9/3A inhibitors and inducers. Methods This was a 3-part, open-label study. Forty-eight healthy subjects received single 20 mg doses of avatrombopag alone or with one of 3 CYP2C9/3A inhibitors or inducers: fluconazole 400 mg once daily for 16 days, itraconazole 200 mg twice daily on Day 1 and 200 mg once daily on Days 2-16, or rifampin 600 mg once daily for 16 days. Pharmacokinetics, pharmacodynamics (platelet count), and safety of avatrombopag were evaluated. Results Co-administration of a single 20-mg dose of avatrombopag with fluconazole at steady-state resulted in 2.16-fold increase of AUC of avatrombopag, prolonged t½ (from 19.7 h to 39.9 h) and clinically significant increase in Emax (1.66-fold). Itraconazole had a mild increase on both avatrombopag pharmacokinetics and pharmacodynamics compared to fluconazole. Co-administration of rifampin caused a 0.5-fold decrease in AUC, shortened t½ (from 20.3 h to 9.84 h), and without any impact of Emax. Co-administration with interacting drugs was found to be generally safe and well-tolerated. Conclusions The results from co-administration of fluconazole or itraconazole suggest that CYP2C9 plays a predominant role in metabolic clearance of avatrombopag than CYP3A. To achieve comparable platelet count increases when avatrombopag is co-administered with CYP3A and CYP2C9 inhibitors, an adjustment in the dose or duration of treatment is recommended, while co-administration with strong inducers is not currently recommended.

Publisher URL: http://onlinelibrary.wiley.com/resolve/doi

DOI: 10.1111/bcp.13517

You might also like
Discover & Discuss Important Research

Keeping up-to-date with research can feel impossible, with papers being published faster than you'll ever be able to read them. That's where Researcher comes in: we're simplifying discovery and making important discussions happen. With over 19,000 sources, including peer-reviewed journals, preprints, blogs, universities, podcasts and Live events across 10 research areas, you'll never miss what's important to you. It's like social media, but better. Oh, and we should mention - it's free.

  • Download from Google Play
  • Download from App Store
  • Download from AppInChina

Researcher displays publicly available abstracts and doesn’t host any full article content. If the content is open access, we will direct clicks from the abstracts to the publisher website and display the PDF copy on our platform. Clicks to view the full text will be directed to the publisher website, where only users with subscriptions or access through their institution are able to view the full article.